What is picroside and where does it come from?

Picroside refers primarily to picroside-I and picroside-II, iridoid glycoside compounds isolated from the rhizomes and roots of Picrorhiza kurroa (Kutki), a Himalayan alpine herb growing at 3,000–5,000 meters elevation. Picroside-I has a molecular formula of C₂₄H₂₈O₁₁ and a molecular weight of 492.47 g/mol, and can be isolated at 98% purity using reversed-phase HPLC. These compounds are the principal bioactive constituents responsible for the plant's documented hepatoprotective and anti-inflammatory properties in preclinical studies.

What are the main health benefits of picroside?

Picroside-I and picroside-II have demonstrated hepatoprotective, anti-inflammatory, antimicrobial, and chondroprotective activities in preclinical research. Picroside-II suppresses the MAPK/NF-κB/NLRP3 inflammasome axis to protect chondrocytes from pyroptosis in osteoarthritis models, while picroside-I inhibits Yersinia enterocolitica with a minimum inhibitory concentration of 2.45 mg/mL. Crude extracts containing these compounds produce 46–65% inhibition of ear swelling in murine anti-inflammatory assays, reflecting significant biological activity that awaits confirmation in human clinical trials.

Is picroside safe to take, and are there any drug interactions?

Formal human safety studies for isolated picroside-I or picroside-II have not been published, meaning no established maximum safe dose or confirmed drug interaction profile exists for these compounds. Traditional Ayurvedic use of whole Picrorhiza kurroa preparations over centuries suggests general tolerability at conventional herbal doses, but this does not substitute for rigorous clinical toxicology data. Individuals taking hepatically-metabolized drugs, immunosuppressants, or anti-inflammatory medications should consult a healthcare provider before using picroside-containing products, and use during pregnancy or lactation is not advised.

What is the difference between picroside and Picroliv?

Picroside refers to individual iridoid glycoside compounds — specifically picroside-I and picroside-II — isolated from Picrorhiza kurroa, whereas Picroliv is a standardized, multi-component commercial extract developed by India's Central Drug Research Institute that contains a defined mixture of picroside-I, kutkoside, and related constituents. Picroliv is the most studied formulation for hepatoprotective applications and represents the closest translation of traditional Kutki use into a reproducible pharmaceutical-grade preparation. Individual picrosides are primarily used as reference standards and research tools, whereas Picroliv is used in herbal medicine and investigational hepatology research.

Has picroside been tested in human clinical trials?

As of the current evidence base, no published human randomized controlled trials reporting defined patient populations, sample sizes, or quantified clinical effect sizes for isolated picroside-I or picroside-II have been identified. Available evidence is limited to in vitro biochemical assays, cell culture models, and rodent studies, which demonstrate clear biological plausibility but do not confirm clinical efficacy or safety in humans. The evidence score for picroside is therefore classified as preliminary (score: 4 out of 10), reflecting meaningful preclinical data without supporting clinical trial validation.

What is the difference between Picroliv and pure picroside extracts?

Picroliv is a standardized mixture containing both picroside-I and kutkoside, while pure picroside refers to individual picroside compounds isolated from Picrorhiza kurroa. Picroliv is the more extensively studied formulation in clinical research, particularly for hepatoprotection, and typically shows superior efficacy for liver support compared to picroside alone due to the synergistic action of its multiple active constituents. Pure picroside extracts may offer targeted effects but lack the robust clinical evidence base that Picroliv possesses.

How much picroside or Picroliv should I take daily for liver support?

Clinical trials investigating Picroliv for hepatoprotection have typically used doses ranging from 400–500 mg daily in divided doses, though optimal dosing can vary based on the specific formulation and standardization percentage. The ideal dosage depends on whether you are using pure picroside extract or a standardized Picroliv preparation, as concentration levels differ significantly between products. It is recommended to follow product labeling or consult with a healthcare provider to determine the appropriate dose for your individual needs and health status.

What does research show about picroside's anti-inflammatory effectiveness?

Preclinical studies demonstrate that crude Picrorhiza kurroa extracts and picroside-II inhibit mouse ear swelling by 65% and 46% respectively at 6 hours, indicating notable anti-inflammatory activity through modulation of oxidative stress pathways and NF-κB suppression. While these animal model results are promising, most high-quality clinical evidence focuses on Picroliv rather than isolated picroside for inflammatory conditions. Further human trials are needed to establish the specific anti-inflammatory efficacy and optimal therapeutic applications of picroside in clinical practice.

Picroside

Picroside-I and picroside-II are iridoid glycosides that exert hepatoprotective, anti-inflammatory, and antimicrobial effects by modulating NF-κB signaling, inhibiting MAPK/NLRP3 pyroptosis pathways, and targeting bacterial dihydrofolate reductase (DHFR). Preclinical evidence demonstrates that picroside-II suppresses chondrocyte destruction in osteoarthritis models via MMP3 downregulation and Col2 upregulation, while picroside-I exhibits antimicrobial activity against Yersinia enterocolitica with a zone of inhibition of 23.3 ± 0.34 mm and an MIC of 2.45 mg/mL.

Category: Compound Evidence: 1/10 Tier: Preliminary

Origin & History

Picroside-I and picroside-II are iridoid glycoside compounds isolated from the rhizomes and roots of Picrorhiza kurroa (Kutki), a small perennial herb native to the alpine Himalayan region of India, Nepal, and Pakistan, typically growing at elevations between 3,000 and 5,000 meters. The plant thrives in rocky, moist soils along stream banks and cliff faces in cold, high-altitude environments. Picrorhiza kurroa has been cultivated and wildcrafted for centuries across the Indian subcontinent as a cornerstone of Ayurvedic medicine, though overharvesting has rendered it a threatened species in several regions.

Historical & Cultural Context

Picrorhiza kurroa, known as Kutki or Katuki in Sanskrit and Hindi, has been used for over two millennia as a foundational bitter tonic in Ayurvedic medicine, referenced in classical texts including the Charaka Samhita and Sushruta Samhita for the treatment of liver disorders, fevers, and digestive ailments. The plant's intensely bitter rhizome was traditionally prepared as a powder, decoction, or incorporated into compound Ayurvedic formulations (e.g., Arogyavardhini Vati) for jaundice, malaria, and respiratory conditions, establishing its role as a hepatoprotective and antipyretic long before its chemical constituents were characterized. In Tibetan medicine, Picrorhiza kurroa is similarly recognized under the name Hong-len and used for its bitter digestive and liver-supporting properties. The isolation and characterization of picroside-I and picroside-II in the modern era validated the chemical basis of these traditional applications, with the standardized extract Picroliv developed by the Central Drug Research Institute of India as an attempt to translate Ayurvedic hepatoprotective knowledge into a reproducible pharmaceutical preparation.

Health Benefits

- **Hepatoprotection**: Picroliv, a standardized mixture of picroside-I and kutkoside, is the most studied formulation for liver protection, with preclinical data indicating modulation of oxidative stress pathways and NF-κB suppression relevant to hepatocellular injury.
- **Anti-inflammatory Activity**: Crude extracts and picroside-II demonstrate 65% and 46% inhibition of mouse ear swelling at 6 hours, respectively, suggesting significant anti-edema and anti-inflammatory potential mediated through NF-κB p65 cysteine modification.
- **Antimicrobial Effects**: Picroside-I inhibits Yersinia enterocolitica by binding dihydrofolate reductase via hydrophilic and hydrophobic interactions, achieving a minimum inhibitory concentration of 2.45 mg/mL and causing observable bacterial cell lysis by scanning electron microscopy.
- **Osteoarthritis Chondroprotection**: Picroside-II suppresses MAPK, NF-κB, and NLRP3 inflammasome-driven pyroptosis in chondrocytes, reducing MMP3 expression and restoring type II collagen (Col2) synthesis in in vitro osteoarthritis models.
- **Apoptosis Potentiation**: Picroliv modifies the cysteine residue within the NF-κB p65 subunit, suppressing NF-κB-regulated anti-apoptotic gene expression and potentially sensitizing aberrant cells to programmed cell death.
- **Antioxidant Support**: Picrorhiza kurroa extracts, by virtue of their iridoid glycoside content including picrosides-I and -II, contribute to reduction of oxidative stress markers in hepatic tissue in animal studies, supporting their traditional Ayurvedic use for liver health.

How It Works

Picroside-I exerts antimicrobial effects by binding to dihydrofolate reductase (DHFR) of Yersinia enterocolitica through a combination of hydrophilic and hydrophobic molecular interactions, disrupting folate biosynthesis and inducing bacterial cell lysis as confirmed by scanning electron microscopy. Picroside-II inhibits the convergent MAPK/NF-κB/NLRP3 inflammasome signaling cascade in chondrocytes, suppressing pyroptosis and reducing matrix metalloproteinase-3 (MMP3) expression while upregulating type II collagen, thereby protecting extracellular matrix integrity in articular cartilage. Picroliv (a picroside-enriched standardized fraction) covalently modifies the cysteine residue in the p65 subunit of NF-κB, blocking transcription of NF-κB-regulated pro-survival and pro-inflammatory genes and potentiating apoptotic signaling in susceptible cell types. Collectively, these mechanisms converge on reduction of inflammatory cytokine signaling, bacterial metabolic disruption, and restoration of cellular redox balance, explaining the broad bioactivity profile observed across preclinical disease models.

Scientific Research

The existing evidence base for picrosides is composed almost entirely of in vitro biochemical assays and rodent model studies, with no published human randomized controlled trials reporting sample sizes or quantified clinical effect sizes for picroside-I or picroside-II as isolated compounds. Antimicrobial activity has been rigorously characterized in vitro, including zone-of-inhibition measurements (23.3 ± 0.34 mm), MIC (2.45 mg/mL), and minimum bactericidal concentration (2.4 mg/mL) against Yersinia enterocolitica, with structural confirmation via RP-HPLC (98% purity), LC-MS, and NMR. Anti-inflammatory effects in mice (46–65% ear swelling inhibition) and chondroprotective effects in cell culture (Western blot, qRT-PCR, immunofluorescence with p<0.05 significance implied) represent the strongest mechanistic data available, but these findings lack translation into powered clinical trials. The hepatoprotective formulation Picroliv has the longest history of investigation in animal liver injury models, yet rigorous peer-reviewed clinical trial data in humans remain absent from published literature, significantly limiting evidence-based dosage recommendations.

Clinical Summary

No human clinical trials with defined patient populations, randomized designs, or reported statistical effect sizes have been identified for isolated picroside-I or picroside-II. Hepatoprotective properties have been most extensively evaluated using Picroliv (a standardized multi-component picroside fraction from Picrorhiza kurroa) in preclinical hepatotoxicity models, yielding promising but not clinically validated outcomes. Anti-inflammatory and chondroprotective outcomes have been measured in murine and cell-based systems, with quantified endpoints (percent inhibition, protein and mRNA expression ratios) that demonstrate biological plausibility but do not constitute clinical evidence. Confidence in clinical efficacy is therefore low, and translation of preclinical findings to human therapeutic application requires well-designed phase I and phase II trials with standardized picroside preparations.

Nutritional Profile

Picroside-I (C₂₄H₂₈O₁₁, molecular weight 492.47 g/mol, melting point 128–130 °C) and picroside-II are iridoid glycosides and are not macronutrients; they do not contribute meaningful caloric, protein, fat, or carbohydrate content at supplemental doses. The Picrorhiza kurroa rhizome also contains kutkoside, dihydromikanolide, pikuroside, 6-feruloyl catalpol, and minor phenolic constituents identified by LC-MS, contributing to the overall bioactivity profile of whole-plant preparations. Precise weight-percentage concentrations of picroside-I and picroside-II in raw dried rhizome material have not been definitively established in published sources, though ethanolic extracts active in bioassays contain measurable concentrations quantifiable by TLC densitometry and RP-HPLC. Bioavailability of picroside glycosides is hypothesized to involve intestinal deglycosylation to aglycone forms, but human pharmacokinetic data confirming absorption, distribution, metabolism, and excretion parameters are not yet available.

Preparation & Dosage

- **Standardized Extract (Picroliv)**: The most studied commercial form contains a defined ratio of picroside-I and kutkoside; typical investigational doses in animal studies correspond to extrapolated human-equivalent ranges of 75–400 mg/day, but no validated human clinical dose has been established.
- **Ethanolic Rhizome Extract**: Active concentrations in bioassay systems range from 0.234 to 15 mg/mL; whole ethanolic extracts are used in traditional Ayurvedic compound formulations.
- **TLC-Standardized Powders**: Picroside-I and picroside-II are quantified by TLC densitometry in commercial herbal preparations; standardization to ≥1% total picrosides is referenced in some herbal pharmacopoeias.
- **Traditional Ayurvedic Preparation**: Dried rhizome powder of Kutki is prepared as a water decoction or churna (fine powder) at traditional doses of 1–3 g/day in classical Ayurvedic texts.
- **Timing Note**: No pharmacokinetic data on optimal dosing timing, meal interactions, or steady-state kinetics are available for isolated picrosides in humans.
- **Isolation-Grade Compound**: Picroside-I isolated at 98% purity via RP-HPLC and column chromatography is used for research purposes and is not available as a consumer supplement in pure form.

Synergy & Pairings

Picroside-containing extracts (Picroliv) are traditionally combined with Silymarin (from Silybum marianum) in integrative hepatoprotective protocols, as both compounds address oxidative stress and NF-κB-mediated hepatic inflammation through partially complementary mechanisms, potentially offering additive hepatocyte protection. Picroside-II's NLRP3 inflammasome inhibition may synergize with other natural NF-κB modulators such as curcumin (from Curcuma longa), which also targets p65 and IκB kinase, providing overlapping but mechanistically distinct anti-inflammatory coverage. No formally studied synergistic combinations with quantified pharmacodynamic interaction data have been published for isolated picrosides, and proposed combinations remain empirical.

Safety & Interactions

The safety profile of isolated picroside-I and picroside-II in humans has not been formally established through clinical toxicology studies, and no maximum tolerated dose, no-observed-adverse-effect level (NOAEL), or established upper limit has been published for these compounds as isolated entities. Whole Picrorhiza kurroa preparations, including Picroliv, have been used in Ayurvedic practice for centuries with a traditional assumption of tolerability, but systematic adverse event reporting, drug interaction studies, and long-term safety data in human populations are absent from the peer-reviewed literature. Potential interactions with immunosuppressant drugs, hepatically-metabolized pharmaceuticals (CYP enzyme substrates), and anticoagulants are theoretically plausible given NF-κB pathway modulation but remain uninvestigated. Use during pregnancy and lactation is not recommended due to complete absence of safety data, and individuals with autoimmune conditions or those taking prescription anti-inflammatory or hepatotoxic medications should consult a clinician before use.